MN-CWT
25.4.2022 14:02:06 CEST | Business Wire | Press release
CWT, the Business-to-Business-for-Employees (B2B4E) travel management platform, announces that Michelle McKinney Frymire has decided to step down from her roles at the Company. As part of the Company’s long-term succession planning process, the Board of Directors has appointed President and Chief Commercial Officer Patrick Andersen as its next President and Chief Executive Officer, effective May 1, 2022. He will also serve on the Company’s Board of Directors.
“Leading CWT through such a critical phase in its evolution has been a great honor,” said McKinney Frymire. “We have made substantial achievements during extraordinary times, and I am grateful to our global team and customers for their trust and supportive partnership. Now, with a strong financial foundation in place, CWT is positioned to accelerate its growth plan and I’m pleased to pass the baton to Patrick.”
“We are excited that Patrick will serve as our next CEO, given his outstanding track record as Chief Commercial Officer and 13 years in international leadership roles at CWT. He has deep-rooted relationships with our customers and stakeholders and has demonstrated superb leadership through overseeing our strategic priorities, expanding RoomIt, and launching our groundbreaking myCWT China technology platform,” said Jim Abrahamson, Chair of the CWT Board. “On behalf of the Board and our global colleagues, we thank Michelle for her many contributions since she joined the Company in 2019 and wish her well in her next endeavors.”
“I’m delighted and honored to lead CWT to its next stage of growth,” said Patrick Andersen. “As travel demand increases, CWT is well positioned to invest in and expand its industry leadership and global relationships. Importantly, I’ll continue our commitment to our core values and look forward to working with our Board and the CWT team to enhance our technology, and further strengthen the travel and events services we provide to our customers around the world.”
Prior to his role as President and Chief Commercial Officer, Mr. Andersen served as Chief Strategy Officer and before that President of the Americas. Since joining the Company in 2008, Mr. Andersen has managed and overseen several industry-defining initiatives including the launch of myCWT China, expanding RoomIt by CWT, and developing innovative long-term GDS technology partnership agreements. He has over 30 years’ experience in global travel & logistics, with various international leadership roles at Deutsche Post Worldwide and DHL. Andersen also serves as a Non-Executive Member of the Board at Global Minnesota, and MNSNAP, and is on the Board of Overseers for the Carlson School of Management. He studied management at the London Business School.
About CWT
CWT is a Business-to-Business-for-Employees (B2B4E) travel management platform on whom companies and governments rely on to keep their people connected. Anywhere, anytime, anyhow – across six continents – the company provides their clients and their employees with innovative technology and an efficient, safe, and secure travel experience.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220424005089/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
